Clinical and sociodemographic characterization of multiple myeloma patients with symptomatic relapse and/or refractory disease under treatment in Portugal: an observational, multicenter study

被引：0
|
作者：
Bergatim, Rui [1 ,2 ,3 ,4 ]
Freitas, Jose Guilherme [5 ]
Goncalves, Cristina [6 ,7 ]
Martins, Helena [8 ]
Marques, Herlander [9 ,10 ,11 ]
Coelho, Henrique [12 ]
Seabra, Patricia [6 ]
Roque, Adriana [13 ,14 ]
Ferreira, Marcio Marcio [15 ]
Pinto, Pedro [16 ]
Francisco, Ana Rita [17 ]
Tato, Joana [17 ]
Geraldes, Catarina [18 ,19 ,20 ,21 ,22 ,23 ]
机构：
[1] Univ Porto, I3S Inst Invest Inovacao Saude, P-4200135 Porto, Portugal
[2] Univ Porto, Canc Drug Resistance Grp, IPATIMUP Inst Mol Pathol & Immunol, P-4200135 Porto, Portugal
[3] Hosp Ctr Sao Joao, Clin Hematol, P-4200319 Porto, Portugal
[4] Univ Porto, Fac Med, Clin Hematol, P-4200319 Porto, Portugal
[5] Inst Portugues Oncol Porto, Serv Oncohematol, Porto, Portugal
[6] Ctr Hosp Univ Santo Antonio, Serv Hematol, Porto, Portugal
[7] Prof Auxiliar Convidada ICBAS, Lisbon, Portugal
[8] Ctr Hosp Lisboa Norte, Hosp Santa Maria, EPE, Lisbon, Portugal
[9] Hosp Braga, Serv Oncol, Braga, Portugal
[10] Ctr Clin Acad Braga CCA, Braga, Portugal
[11] CINTESIS Ctr Invest Tecnl & Serv Saude, Porto, Portugal
[12] Ctr Hosp Vila Nova de Gaia Espinho EPE, Vila Nova De Gaia, Portugal
[13] Ctr Hosp & Univ Coimbra, Clin Hematol, Coimbra, Portugal
[14] Univ Coimbra, Inst Physiol, Fac Med, Coimbra, Portugal
[15] Braga Hosp, Clin Hematol, Braga, Portugal
[16] Ctr Hosp Vila Nova de Gaia Espinho, Clin Hematol, Vila Nova De Gaia, Portugal
[17] Takeda Farmaceut Portugal, Lisbon, Portugal
[18] Ctr Hosp & Univ Coimbra, Clin Hematol, Coimbra, Portugal
[19] Univ Coimbra, Fac Med, Lab Oncobiol & Hematol, Coimbra, Portugal
[20] Univ Coimbra, Fac Med, Clin Univ Hematol, Coimbra, Portugal
[21] Univ Coimbra, Fac Med, Coimbra Inst Clin & Biomed Res ICBR, Grp Invest Ambiente Genet & Oncobiogia CIMAGO, Coimbra, Portugal
[22] Ctr Inovacao Biomed & Biotecnol, Coimbra, Portugal
[23] Ctr Acad Clin Coimbra, Coimbra, Portugal
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-235
引用
收藏
页码：S165 / S165
页数：1
相关论文
共 50 条
  • [21] CLINICAL AND TREATMENT CHARACTERISTICS OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN EUROPE
    Oriol, A.
    Steinmetz, T.
    Patel, V
    Kutikova, L.
    Schmidt, N.
    Hennies, N.
    Thiess, A.
    Kostev, K.
    Leleu, X.
    VALUE IN HEALTH, 2019, 22 : S497 - S498
  • [22] Feasibility of a Clinical Decision Support Tool for Ustekinumab to Predict Clinical Remission and Relapse in Patients With Crohn's Disease: A Multicenter Observational Study
    Park, Jihye
    Chun, Jaeyoung
    Yoon, Hyuk
    Cheon, Jae Hee
    INFLAMMATORY BOWEL DISEASES, 2023, 29 (04) : 548 - 554
  • [23] Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study
    Kumar, S.
    Crowley, J.
    Klein, S. K.
    Lahuerta, J. J.
    Lee, J.
    Moreau, P.
    Morgan, G.
    Richardson, P. G.
    Siegel, D. S.
    Durie, B. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] Duration of Treatment of Multiple Myeloma Regimens in Patients with Relapsed or Refractory Multiple Myeloma: Findings in US Clinical Practice Settings
    Potluri, Ravi
    Kanakamedala, Hemanth
    Chen, Clara
    Yasenchak, Christopher A.
    Ranjan, Sandip
    Papademetriou, Eros
    Bhandari, Hitesh
    Mann, Jasdeep
    Davis, Catherine
    BLOOD, 2017, 130
  • [25] Improved Response Rates with Bortezomib in Relapsed or Refractory Multiple Myeloma: An Observational Study in Chinese Patients
    Lin, MaoFang
    Hou, Jian
    Chen, WenMing
    Huang, XiaoJun
    Liu, ZhuoGang
    Zhou, YuHong
    Li, Yan
    Zhao, Taiyun
    Wang, LinNa
    Wu, Kwang-Wei
    Shen, ZhiXiang
    ADVANCES IN THERAPY, 2014, 31 (10) : 1082 - 1094
  • [26] Improved Response Rates with Bortezomib in Relapsed or Refractory Multiple Myeloma: An Observational Study in Chinese Patients
    MaoFang Lin
    Jian Hou
    WenMing Chen
    XiaoJun Huang
    ZhuoGang Liu
    YuHong Zhou
    Yan Li
    Taiyun Zhao
    LinNa Wang
    Kwang-Wei Wu
    ZhiXiang Shen
    Advances in Therapy, 2014, 31 : 1082 - 1094
  • [27] A MULTICENTER, OPEN LABEL STUDY OF VELCADE, MELPHALAN AND PREDNISONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS
    Petrucci, M. T.
    Gentilini, F.
    Bringhen, S.
    Scotti, S.
    Levi, A.
    Siniscalchi, A.
    Larocca, A.
    Calabrese, E.
    Foa, R.
    Palumbo, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 587 - 587
  • [28] Daratumumab in Indian patients with relapsed and refractory multiple myeloma: a prospective, multicenter, phase IV study
    Kumar, Lalit
    Melinkeri, Sameer
    Ganesan, Prasanth
    Kumar, Jeevan
    Biswas, Ghanashyam
    Kilara, Nalini
    Pathalingappa, Harish
    Prasad, S. V. S. S.
    Jain, Minish
    Mishra, Sourav Kumar
    Prasad, Saurabh
    Boyella, Pavan Kumar
    Sahoo, Ranjit Kumar
    Bondarde, Shailesh
    Shah, Sandip
    Rege, Milind
    Deb, Uttiya
    Korde, Tanuja
    Dixit, Jitendra
    FUTURE ONCOLOGY, 2024, 20 (04) : 191 - 205
  • [29] Role of D(T)PACE-based regimens as treatment of multiple myeloma with extramedullary relapse or refractory disease
    Huynh, Tony
    Corre, Elise
    Lemonnier, Marie-Paule
    Dulery, Remy
    Marjanovic, Zora
    Jaff, Nabaz
    Lapusan, Simona
    Mohty, Mohamad
    Garderet, Laurent
    Coppo, Paul
    LEUKEMIA & LYMPHOMA, 2021, 62 (09) : 2235 - 2241
  • [30] COMPARATIVE STUDY OF THE CLINICAL-BIOLOGICAL CHARACTERISTICS TO THE DIAGNOSIS AND RELAPSE IN PATIENTS WITH MULTIPLE MYELOMA
    Villalba Valenzuela, A.
    Romero Dominguez, S.
    Santiago Balsera, M.
    Freiria Alberte, C.
    Arnao Herraiz, M.
    Andreu Lapiedra, R.
    Perla Muedra, A.
    Dominguez Malfeito, E.
    Jarque Ramos, I
    HAEMATOLOGICA, 2018, 103 : 121 - 122
12345